Exelixis’s Cabometyx advances mCRPC treatment with big trial validation questions
Exelixis has announced the detailed results of the CONTACT-02 (NCT04446117) Phase III pivotal trial that assessed the combination of Cabometyx…
Clinical Trials Analysis
Novel therapies to drive PD market across 7MM to $6.4 billion in 2029
Pharma world braces for major changes in new era of AI
Celebrating Clinical Trials Day
Breast Cancer accounts for 12.2% share of global Oncology clinical trial activity in 2020
Lupus Erythematosus accounts for 8.2% share of global Immunology clinical trial activity in 2020
Schizophrenia accounts for 2.9% share of global Central Nervous System clinical trial activity in 2020
Depression accounts for 7.6% share of global Central Nervous System clinical trial activity in 2020
